Key facts
- This page summarizes Molly Joel Coye's Form 4 filing for AMEDISYS INC (AMED).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2025, 16:03.
Molly Joel Coye - 14 Aug 2025 Form 4 Insider Report for AMEDISYS INC (AMED)
- Reporting relationship
- Director
- Issuer ticker
- AMED
- Reported as of
- 14 Aug 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2025, 16:03:25 UTC
- Prior SEC filing
- 06 May 2025
- Source filing
- View source filing
- Reporting owner signature
- Jennifer Guckert Griffin, pursuant to a power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Molly Joel Coye filed Form 4 for AMEDISYS INC (AMED) on 14 Aug 2025.
Change
- Previous filing in this sequence was filed on 06 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001338682
Primary reporting owner
Coye Molly Joel
- Relationship
- Director
- Address
- 3854 AMERICAN WAY, SUITE A, BATON ROUGE
- Signature
- Jennifer Guckert Griffin, pursuant to a power of attorney
- Signature date
- 14 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMED
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -8,818
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Aug 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Molly Joel Coye is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.
Footnote F2
Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.